Next Generation Modalities in Drug Discovery & Development
BIOL-40394
Participants will delve into the science and technology behind novel therapeutic approaches such as gene therapy, RNA-based therapies, cell-based treatments, and biologics including monoclonal antibodies and biosimilars. The course will cover the principles of designing, developing, and evaluating these innovative therapies, emphasizing the regulatory and clinical challenges associated with their development. Through a combination of theoretical lectures, case studies, and interactive discussions, students will gain a comprehensive understanding of how these new modalities are integrated into the drug development pipeline, from initial discovery to market approval. This course is ideal for professionals in pharmaceutical and biotech industries, researchers, and regulatory affairs specialists looking to stay at the forefront of therapeutic innovation.
Course Information
Course sessions
Section ID:
Class type:
This course is entirely web-based and to be completed asynchronously between the published course start and end dates. Synchronous attendance is NOT required.
You will have access to your online course on the published start date OR 1 business day after your enrollment is confirmed if you enroll on or after the published start date.
Textbooks:
All course materials are included unless otherwise stated.
Policies:
- No refunds after: 5/18/2026
Schedule:
Instructor:
Curtis Thompson
Dr. Curt Thompson is a senior nonclinical drug development expert with extensive experience in oncology, particularly in tumor microenvironment biology. With a focus on advancing programs from candidate selection through IND filing and into clinical support, Dr. Thompson has guided teams in navigating critical development decisions to minimize risk and avoid costly missteps.
Over the course of his career, Dr. Thompson has contributed to programs in oncology, inflammation, osteoarthritis, asthma, diabetes, and other disease areas—working across therapeutic modalities such as small molecules, antibodies, ADCs, RNAi, nanoparticles, and pegylated enzymes. He has led cross-functional teams, collaborated with academic and industry partners, and provided both strategic and scientific insight to drive go/no-go decisions.
Dr. Thompson holds a Master of Biotechnology Enterprise and Entrepreneurship (MBEE) from Johns Hopkins University, equipping him with the ability to bridge science and business. His expertise is especially valuable in startup and early-stage environments, where aligning innovation with strategic execution is key to success.